Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Cash from Financing Activities (2022 - 2024)

CervoMed (CRVO) has disclosed Cash from Financing Activities for 8 consecutive years, with -$13340.0 as the latest value for Q3 2024.

  • Quarterly Cash from Financing Activities fell 100.12% to -$13340.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$13340.0 through Dec 2025, down 100.12% year-over-year, with the annual reading at $4.6 million for FY2025, 90.11% down from the prior year.
  • Cash from Financing Activities hit -$13340.0 in Q3 2024 for CervoMed, up from -$93375.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $11.2 million in Q3 2023 to a low of -$93375.0 in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $2.2 million across 3 years, with a median of -$5000.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: surged 224949.78% in 2023 and later plummeted 100.12% in 2024.
  • Year by year, Cash from Financing Activities stood at -$5000.0 in 2022, then crashed by 1767.5% to -$93375.0 in 2023, then surged by 85.71% to -$13340.0 in 2024.
  • Business Quant data shows Cash from Financing Activities for CRVO at -$13340.0 in Q3 2024, -$93375.0 in Q4 2023, and $11.2 million in Q3 2023.